Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triptorelin + recombinant FSH
- Development stage
- Phase 4
- Lead developer
- Debiopharm
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
This is a combination therapy of two agents used primarily in assisted reproductive technologies, especially in controlled ovarian hyperstimulation protocols for in vitro fertilization (IVF). Triptorelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist that initially stimulates, then suppresses, the pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to downregulation of endogenous gonadotropins. This prevents premature LH surges and ovulation during IVF cycles. Recombinant FSH is a laboratory-produced form of human follicle-stimulating hormone that directly stimulates the growth and maturation of ovarian follicles. The combination allows for precise control over ovarian stimulation by suppressing endogenous hormones with triptorelin while providing exogenous FSH to promote multiple follicular development[2][3][4][7].
- Brand names
- Decapeptyl (for triptorelin)Trelstar (for triptorelin)
- Other names
- GnRH agonist + rFSHgonadotropin-releasing hormone agonist + recombinant follicle-stimulating hormone
02
Targets
FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on triptorelin + recombinant FSH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triptorelin + recombinant FSH.